'Best Results' Yet for Poor-Prognosis Elderly With DLBCL The Oncology Report SAN DIEGO – Stretching out the delivery of rituximab significantly improved overall and event-free survival among older patients with poor-prognosis diffuse large B-cell lymphoma, German investigators reported. Patients older than 60 years who had ... |
